Your misery is no longer my pleasure: Reduced schadenfreude in Huntington's disease families.

Cortex

Laboratory of Experimental Psychology and Neuroscience (LPEN), Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Universidad Autónoma del Caribe, Barranquilla, Colombia; Center for Social and Cognitive Neuroscience (CSCN), School of Psychology, Universidad Adolfo Ibáñez, Santiago de Chile, Chile; Australian Research Council Centre of Excellence in Cognition and its Disorders, Sydney, Australia. Electronic address:

Published: October 2016

Schadenfreude - pleasure at others' misfortunes - has been systematically related to ventral striatum activity. This brain region is affected early in individuals with manifest and pre-manifest Huntington's disease (HD). However, the experience of schadenfreude has not yet been investigated in HD. In this study, 21 manifest HD patients, 19 first-degree asymptomatic relatives, and 23 healthy controls performed an experimental task designed to trigger schadenfreude, envy (another social emotion acting as an affective control condition), and control situations. Both HD patients and first-degree relatives experienced lower schadenfreude in response to others' misfortunes, with no group differences in ratings of envy and control conditions. These results offer unprecedented evidence of a highly specific impairment in reward processing, extending previous reports in manifest and pre-manifest HD individuals. Moreover, these findings suggest that early striatal impairments may be related to reduced feelings of schadenfreude. In sum, our work contributes to the understanding of emotional impairments in early stages of HD, while shedding light on their neural correlates.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cortex.2016.07.009DOI Listing

Publication Analysis

Top Keywords

huntington's disease
8
others' misfortunes
8
manifest pre-manifest
8
patients first-degree
8
schadenfreude
6
misery longer
4
longer pleasure
4
pleasure reduced
4
reduced schadenfreude
4
schadenfreude huntington's
4

Similar Publications

Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.

Neurol Ther

January 2025

Health Economics and Outcomes Research, Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA, 92130, USA.

Introduction: Chorea is the primary manifestation of Huntington's disease. Different clinicians pursue varied approaches to chorea management, and real-world evidence describing them is needed. The objective of this study was to assess the presence and severity of chorea, chorea pharmacotherapy, and treatment practice, and patterns in a large natural-history cohort with Huntington's disease.

View Article and Find Full Text PDF

Disease-Specific Speech Movement Characteristics of the Tongue and Jaw.

J Speech Lang Hear Res

January 2025

Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN.

Purpose: To advance our understanding of disease-specific articulatory impairment patterns in speakers with dysarthria, this study investigated the articulatory performance of the tongue and jaw in speakers with differing neurological diseases (Parkinson's disease [PD], amyotrophic lateral sclerosis, multiple sclerosis, and Huntington's disease).

Method: Fifty-seven speakers with dysarthria and 30 controls produced the sentence "Buy Kaia a kite" five times. A three-dimensional electromagnetic articulography was used to record the articulatory movements of the posterior tongue and jaw.

View Article and Find Full Text PDF

Background: Longitudinal qualitative data on what matters to people with Parkinson's disease are lacking and needed to guide patient-centered clinical care and development of outcome measures.

Objective: To evaluate change over time in symptoms, impacts, and relevance of digital measures to monitor disease progression in early Parkinson's.

Methods: In-depth, online symptom mapping interviews were conducted with 33 people with early Parkinson's at baseline and 1 year later to evaluate (A) symptoms, (B) impacts, and (C) relevance of digital measures to monitor personally relevant symptoms.

View Article and Find Full Text PDF

Total functioning capacity scale in Huntington's disease: natural course over time.

J Neurol

January 2025

LUMC Department of Neurology, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Background And Objectives: The total functioning capacity (TFC) assessment has been integral to Huntington's disease (HD) research and clinical trials, measuring disease stage and progression. This study investigates the natural progression of function in HD, focusing on changes in TFC scores related to age and CAG-repeat length, and evaluates TFC's strengths and weaknesses in longitudinal studies.

Methods: Using Enroll-HD platform's clinical dataset version 5, including Registry-3, we analysed data from 21,079 participants, with 16,083 having an expanded CAG repeat.

View Article and Find Full Text PDF

In Vivo Nanodiamond Quantum Sensing of Free Radicals in Caenorhabditis elegans Models.

Adv Sci (Weinh)

January 2025

Department of Biomaterials & Biomedical Technology (BBT), University Medical Centre Groningen (UMCG), Antonius Deusinglaan 1, Groningen, 9713 AV, The Netherlands.

Free radicals are believed to play a secondary role in the cell death cascade associated with various diseases. In Huntington's disease (HD), the aggregation of polyglutamine (PolyQ) not only contributes to the disease but also elevates free radical levels. However, measuring free radicals is difficult due to their short lifespan and limited diffusion range.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!